KAJIAN PUSTAKA : GEJALA SISA PADA PASIEN TUBERKULOSIS YANG TELAH MENYELESAIKAN OBAT ANTI TUBERKULOSIS
Abstract
Abstrak : Kajian Pustaka: Gejala Sisa Pada Pasien Tuberkulosis Yang Telah Menyelesaikan Obat Anti Tuberkulosis. Sekuel Tuberkulosis adalah gejala sisa pasca tuberkulosis yang terjadi pada pasien tuberkulosis (TB) yang telah menjalani pengobatan lengkap. Sekuel TB dapat ditandai dengan kelainan pada parenkim, saluran pernapasan, pleura/dinding dada, vaskular, dan mediastinum. Sekuel TB seringkali tidak terdiagnosis dan terabaikan selama 50 tahun terakhir, padahal prevalensinya relatif tinggi sehingga angka kejadian gejala sisa pasca tuberkulosis masih belum dapat dihitung secara pasti, namun diperkirakan terdapat 16-50% kasus di dunia. Gangguan saluran napas pada pasca TB berkaitan dengan respon imunologis pasien terhadap pengobatan TB. Penelitian pada hewan coba menunjukkan bahwa respon imun penjamu terhadap Mycobaterium tuberculosis berperan dalam kerusakan jaringan paru. Pengobatan saat ini yaitu pemberian bronkodilator untuk mengurangi gejala sesak napas.
Keywords
Full Text:
PDF (Bahasa Indonesia)References
Akashi, S. et al. (2021) ‘IL-1RA in the supernatant of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus is useful for discriminating active tuberculosis from latent infection’, Journal of Infection and Chemotherapy, 27(4), pp. 617–624. Available at: https://doi.org/10.1016/j.jiac.2020.11.023.
Allwood, B.W. et al. (2021) ‘Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge’, Respiration, 100(8), pp. 751–763. Available at: https://doi.org/10.1159/000512531.
Barlo, N.P. et al. (2011) ‘Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1β in idiopathic pulmonary fibrosis’, Clinical and Experimental Immunology, 166(3), pp. 346–351. Available at: https://doi.org/10.1111/J.1365-2249.2011.04468.X.
Bowen, T., Jenkins, R.H. and Fraser, D.J. (2013) ‘MicroRNAs, transforming growth factor beta-1, and tissue fibrosis’, Journal of Pathology, 229(2), pp. 274–285. Available at: https://doi.org/10.1002/PATH.4119.
Contoli, M. et al. (2017) ‘Long-term effects of inhaled corticosteroids on
sputum bacterial and viral loads in COPD’, European Respiratory Journal, 50(4). Available at: https://doi.org/10.1183/13993003.00451-2017.
Fiogbe, A.A. et al. (2019) ‘Prevalence of lung function impairment in cured pulmonary tuberculosis patients in Cotonou, Benin’, International Journal of Tuberculosis and Lung Disease, 23(2), pp. 195–202. Available at: https://doi.org/10.5588/ijtld.18.0234.
Hsu, D. et al. (2020) ‘Post tuberculosis treatment infectious complications’, International Journal of Infectious Diseases, 92, pp. S41–S45. Available at: https://doi.org/10.1016/J.IJID.2020.02.032.
Khan, R., Malik, N.I. and Razaque, A. (2020) ‘Imaging of Pulmonary Post-Tuberculosis Sequelae’, Pakistan Journal of Medical Sciences, 36(1), p. S75. Available at: https://doi.org/10.12669/PJMS.36.ICON-SUPPL.1722.
Kim, C.J. et al. (2017) ‘Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study’, International Journal of Chronic Obstructive Pulmonary Disease, 12, pp. 1589–1596. Available at: https://doi.org/10.2147/COPD.S128750.
Kumar, V. et al. (2010) ‘Robbins and Cotran: Pathologic Basis of Disease, 8th Edition’, Journal of Neuropathology & Experimental Neurology, 69(2), pp. 214–214. Available at: https://doi.org/10.1097/NEN.0B013E3181CD8DBC.
Martino, M. de et al. (2019) ‘Immune respon to Mycobacterium Tuberculosis : A Narative Review’. Frontier in Pediatric, pp. 1–8.
Meghji, J. et al. (2016) ‘A systematic review of the prevalence and pattern of imaging defined post-TB lung disease’, PLoS ONE, 11(8). Available at: https://doi.org/10.1371/journal.pone.0161176.
Menon, B. et al. (2015) ‘Evaluation of the radiological sequelae after treatment completion in new cases of pulmonary, pleural, and mediastinal tuberculosis’, Lung India, 32(3), pp. 241–245. Available at: https://doi.org/10.4103/0970-2113.156233.
Ravimohan, S. et al. (2018) ‘Tuberculosis and lung damage: From epidemiology to pathophysiology’, European Respiratory Review, 27(147). Available at: https://doi.org/10.1183/16000617.0077-2017.
Spruit, M.A. et al. (2013) ‘An official American thoracic society/European respiratory society statement: Key concepts and advances in pulmonary rehabilitation’, American Journal of Respiratory and Critical Care Medicine, 188(8). Available at: https://doi.org/10.1164/RCCM.201309-1634ST/SUPPL_FILE/EXECUTIVE_SUMMARY.PDF.
Stek, C. et al. (2018) ‘The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy’, Frontiers in Microbiology, 9(October), pp. 1–16. Available at: https://doi.org/10.3389/fmicb.2018.02603.
Yum, H.K. and Park, I.N. (2014) ‘Effect of Inhaled Tiotropium on Spirometric Parameters in Patients with Tuberculous Destroyed Lung’, Tuberculosis and Respiratory Diseases, 77(4), pp. 167–171. Available at: https://doi.org/10.4046/TRD.2014.77.4.167.
DOI: https://doi.org/10.33024/jmm.v7i2.10603
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Jurnal Medika Malahayati
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
